QSAM BIOSCIENCES

QSAM Biosciences, Inc. is committed to advancing the fight against cancer through discovery, development and delivery of effective treatment options to adult and pediatric patients. We aim to develop targeted therapeutic radiopharmaceuticals as safer and more efficacious alternatives to current treatment modalities in order to address large unmet medical needs and underserved patient populations. To that end, QSAM is developing a next-generation radiotherapeutic platform to serve multiple indications... Our lead technology, Samarium-153 DOTMP (CycloSam®), is a clinical-stage bone-seeking radiopharmaceutical designed to safely and precisely deliver targeted radiation to tumors in the skeletal system. CycloSam® delivers the beta-emitting radioisotope, Samarium-153, to areas of rapid bone formation through a chelant, DOTMP, emitting a potent yet controlled dose of radiation treatment directly to the tumor environment while minimizing radiation exposure to healthy tissue... We believe..

Also known as: QSAM Biosciences, Inc., QSAM Therapeutics, Inc.

Primary location: Austin United States